Insider Trading & Ownership of Kate Haviland

Location
Cambridge, MA
Summary
The estimated net worth of Kate Haviland is at least $2,636,411 dollars as of 21 Jul 2025. Kate Haviland is the Chief Executive Officer, Director of Blueprint Medicines Corp and owns shares of Blueprint Medicines Corp stock worth about $2.54M. Kate Haviland is the Director of Bicara Therapeutics Inc. and owns shares of Bicara Therapeutics Inc. (BCAX) stock worth about $98.5K.
Signature
/s/ Melissa Masse, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Kate Haviland and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Sign up to save research and follow filings

Quick Takeaways

  • Kate Haviland has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $2,636,411.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Blueprint Medicines Corp ($2,537,920).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Kate Haviland

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
BPMC Blueprint Medicines Corp Chief Executive Officer, Director $2,537,920 17 Jul 2025
BCAX Bicara Therapeutics Inc. Director $98,491 09 Jun 2025
FULC Fulcrum Therapeutics, Inc. Director 26 Jun 2025

Insider Transactions Reported by Kate Haviland:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .